CRISPR Therapeutics: confirmation holds, +11%
CRISPR Therapeutics stock jumps 11% and confirms its new buy signal
Our view last week
A fresh buy signal just fired on CRISPR Therapeutics stock, after last week's sell signal faded out. This week's technical analysis on the stock: a healthcare sector in a strength phase, signal strength high at 76 out of 100, but price action stays mixed — contracting volume, an indecisive bar — and the entry trigger, a pullback toward the 52 area, hasn't fired yet.
This week's summary
CRISPR Therapeutics stock closes the week up 11.1%, the fourth straight weekly gain, with the ADX climbing — a sign the trend is gaining conviction. The buy signal that fired seven days ago holds: the confirmation week closes higher, even though price action stays mixed, with conflicting rejection bars and buyer dominance fading. This weekly technical analysis follows a stock working back toward its recent highs, to be managed with discipline given the wide volatility.
IQS Phase
56
ordinary
Signal Strength
86
high · wide & volatile
Sizing
FULL
Ranking
#5 / 167
US stocks in progress
Trade P&L %
+11.11%
from signal to date, no stop loss
Rank position
ranks 5th among the 167 Longs already running for US stocks in our ranking, with a signal strength of 86 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +4.33% · monthly +9.53%
CRSP belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content